ReviewLife (Basel, Switzerland)2026
The Role of DaT-SPECT Imaging in the Evaluation of Progressive Supranuclear Palsy.
Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProgressive supranuclear palsy (PSP) is an atypical Parkinsonian disorder characterized by a range of clinical phenotypes, reflecting its multiple subtypes. As a result, accurate diagnosis during life remains challenging, underscoring the need for reliable biomarkers. The present narrative review aims to evaluate whether dopamine transporter single-photon emission computed tomography (DaT-SPECT) can serve as a biomarker in the assessment of PSP.
methodsThe database search identified 31 original research articles relevant to our study objective. Of these, 17 studies included PSP patients and utilized DaT-SPECT as the sole molecular imaging modality; 9 studies combined DaT-SPECT with at least one additional molecular imaging technique; and 5 studies integrated DaT-SPECT with a laboratory-based biomarker of neurodegenerative disease.
resultsDaT-SPECT appears to demonstrate low specificity and variable sensitivity for PSP across studies. DISCUSSION: Combining DaT-SPECT with other diagnostic biomarkers, especially brain magnetic resonance imaging and other nuclear imaging modalities, may improve diagnostic accuracy, especially given its relatively low specificity for PSP. Nevertheless, these initially promising findings need to be validated in large, multicenter studies that include and clearly define multiple, autopsy-confirmed PSP subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.